Clinical Trypanosoma rangeli infection as a complication of Chagas' disease.
Laboratory studies on a group of 20 patients from the Rio Negro Valley, Colombia selected for detailed study showed that 14 gave antibody reactions on immunoassay consistent with Trypanosoma cruzi or T. rangeli infections. Four were diagnosed as having T. rangeli infection, 4 had mixed infections and 6 were infected with T. cruzi alone. Immunoprecipitation analysis showed that sera from T. cruzi-infected patients recognized a similar range of trypomastigote-derived polypeptides as sera from patients in Brazil, and all of the Colombian sera reacted with the 160 kiloDalton (kDa) polypeptide associated with active infection. Although sera from patients with T. rangeli infection alone gave a positive immunofluorescence or ELISA reaction with T. rangeli, they failed to bind to parasite polypeptides by either immunoprecipitation or Western blotting. Intriguingly, sera from patients with mixed infections consistently gave a stronger, but qualitatively similar, binding reaction in immunoprecipitation and Western blotting compared to sera from patients infected with T. cruzi alone.
D000906:Antibodies / Q000032:analysis; D000953:Antigens, Protozoan / Q000032:analysis*; D014355:Chagas Disease / Q000150:complications* / Q000175:diagnosis / Q000276:immunology; D003937:Diagnosis, Differential; D004591:Electrophoresis, Polyacrylamide Gel; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes / Q000032:analysis; D005455:Fluorescent Antibody Technique; D006801:Humans; D007158:Immunologic Techniques; D010455:Peptides / Q000032:analysis; D014345:Trypanosoma / Q000276:immunology*; D014349:Trypanosoma cruzi / Q000276:immunology*; D014352:Trypanosomiasis / Q000150:complications* / Q000175:diagnosis / Q000276:immunology
D000906:Antibodies; D000953:Antigens, Protozoan; D000939:Epitopes; D010455:Peptides